Revance Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Revance Therapeutics, Inc.‘s stocks are currently a part of 150 hedge funds’ portfolios, which represents 80.91% of the total amount of its stocks outstanding. This makes up a total of 54.61M shares of Revance Therapeutics, Inc.. Compared to the previous quarter, the number grew by 3.07% or 1.62M shares more. As for the holding position changes, 30.67% (46) of current hedge fund investors increased the number of shares held, 37.33% (56) of current holders sold a part of the shares held, and 12% (18) closed the holdings completely. 22 hedge funds are new holders of Revance Therapeutics, Inc. stock in Q1 2022, it is 14.67% of total holders.
Hedge funds holding Revance Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 86 |
|---|---|
| Q3 2017 | 84 |
| Q4 2017 | 116 |
| Q1 2018 | 119 |
| Q2 2018 | 110 |
| Q3 2018 | 110 |
| Q4 2018 | 99 |
| Q1 2019 | 111 |
| Q2 2019 | 111 |
| Q3 2019 | 106 |
| Q4 2019 | 133 |
| Q1 2020 | 128 |
| Q2 2020 | 141 |
| Q3 2020 | 151 |
| Q4 2020 | 149 |
| Q1 2021 | 147 |
| Q2 2021 | 158 |
| Q3 2021 | 156 |
| Q4 2021 | 148 |
| Q1 2022 | 150 |
Hedge funds changes in Revance Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 13 | 36 | 22 | 4 | 11 |
|---|---|---|---|---|---|
| Q3 2017 | 9 | 32 | 28 | 11 | 4 |
| Q4 2017 | 39 | 45 | 19 | 7 | 6 |
| Q1 2018 | 21 | 52 | 25 | 18 | 3 |
| Q2 2018 | 15 | 47 | 28 | 23 | -3 |
| Q3 2018 | 13 | 34 | 30 | 14 | 19 |
| Q4 2018 | 11 | 35 | 31 | 21 | 1 |
| Q1 2019 | 20 | 52 | 14 | 9 | 16 |
| Q2 2019 | 20 | 42 | 25 | 18 | 6 |
| Q3 2019 | 12 | 50 | 21 | 17 | 6 |
| Q4 2019 | 41 | 46 | 27 | 14 | 5 |
| Q1 2020 | 18 | 50 | 38 | 21 | 1 |
| Q2 2020 | 26 | 64 | 33 | 13 | 5 |
| Q3 2020 | 22 | 64 | 38 | 12 | 15 |
| Q4 2020 | 28 | 51 | 45 | 27 | -2 |
| Q1 2021 | 16 | 58 | 50 | 17 | 6 |
| Q2 2021 | 24 | 55 | 44 | 13 | 22 |
| Q3 2021 | 16 | 56 | 43 | 18 | 23 |
| Q4 2021 | 32 | 56 | 40 | 37 | -17 |
| Q1 2022 | 22 | 46 | 56 | 18 | 8 |
Hedge funds changes in Revance Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 776,000 | 909,000 |
|---|---|---|
| Q3 2017 | 727,885 | 700,000 |
| Q4 2017 | 17,009,870,925 | 16,902,000 |
| Q1 2018 | 3,140,000 | 1,353,000 |
| Q2 2018 | 2,937,000 | 2,191,000 |
| Q3 2018 | 2,081,000 | 1,942,000 |
| Q4 2018 | 944,000 | 466,000 |
| Q1 2019 | 1,136,000 | 939,000 |
| Q2 2019 | 740,000 | 1,462,000 |
| Q3 2019 | 1,408,000 | 1,615,000 |
| Q4 2019 | 1,646,000 | 2,081,000 |
| Q1 2020 | 1,660,000 | 869,000 |
| Q2 2020 | 5,453,000 | 1,090,000 |
| Q3 2020 | 7,416,000 | 10,505,000 |
| Q4 2020 | 6,533,000 | 13,213,000 |
| Q1 2021 | 9,557,000 | 9,030,000 |
| Q2 2021 | 6,678,000 | 11,227,000 |
| Q3 2021 | 7,133,000 | 10,444,000 |
| Q4 2021 | 11,740,000 | 9,782,000 |
| Q1 2022 | 27,488,000 | 10,218,000 |